Prognostic Impact of MCPyV and TIL Subtyping in Merkel Cell Carcinoma: Evidence from a Large European Cohort of 95 Patients.
Aged
Aged, 80 and over
CD8-Positive T-Lymphocytes
/ immunology
Carcinoma, Merkel Cell
/ immunology
Cohort Studies
Europe
Female
Humans
Kaplan-Meier Estimate
Lymphocytes, Tumor-Infiltrating
/ immunology
Male
Merkel cell polyomavirus
Middle Aged
Polyomavirus Infections
/ complications
Prognosis
Retrospective Studies
Skin Neoplasms
/ immunology
Tumor Virus Infections
/ complications
: Merkel cell carcinoma
Immunoscore
Merkel cell polyomavirus
Tumor-infiltrating lymphocytes (TILs)
Journal
Endocrine pathology
ISSN: 1559-0097
Titre abrégé: Endocr Pathol
Pays: United States
ID NLM: 9009288
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
pubmed:
7
12
2019
medline:
1
12
2020
entrez:
7
12
2019
Statut:
ppublish
Résumé
Merkel cell carcinoma is a rare (∼ 2000 cases/year in the USA) but aggressive neuroendocrine neoplasm of the skin. In 2008, the Merkel cell polyomavirus (MCPyV) was found to be clonally integrated in approximately 80% of Merkel cell carcinomas. The remaining 20% have large numbers of UV-associated mutations. Importantly, both the UV-induced neoantigens in virus-negative Merkel cell carcinoma and the Merkel cell polyomavirus oncogenes that are required for virus-positive tumor growth are highly immunogenic. Indeed, antigen-specific T cells detected in patients are frequently "dysfunctional/exhausted," and the inhibitory ligand PD-L1 is often expressed by Merkel cell carcinoma cells. These data led to point our attention on the quantity and the quality of the immune response in Merkel cell carcinoma. Here, we found CD8+ lymphocytes are the only singly evaluated lymphocyte subclass that strongly influenced overall survival and disease-specific survival in Merkel cell carcinoma. In addition, we highlighted as Merkel cell polyomavirus is a strong prognostic factor and as it prompts a host immune response involving various lymphocyte subclasses (CD3, CD8, FoxP3, and PD-L1 positive) in MCC. For this reason, we proposed a novel eye-based "immunoscore" model, obtained by tumor infiltrating lymphocytes subtyping (CD3, CD8, FoxP3, and PD-L1) that could provide additional prognostic information in Merkel cell carcinoma.
Identifiants
pubmed: 31808008
doi: 10.1007/s12022-019-09601-5
pii: 10.1007/s12022-019-09601-5
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
21-32Références
Clin Cancer Res. 2016 Nov 15;22(22):5553-5563
pubmed: 27166398
Cancer. 2007 Aug 1;110(3):640-7
pubmed: 17599745
Oncotarget. 2017 Jun 20;8(25):41011-41020
pubmed: 28487502
Science. 2008 Feb 22;319(5866):1096-100
pubmed: 18202256
J Clin Oncol. 2011 Apr 20;29(12):1539-46
pubmed: 21422430
Lancet Oncol. 2016 Oct;17(10):1374-1385
pubmed: 27592805
Am J Surg Pathol. 1980 Jun;4(3):211-21
pubmed: 7396063
Oncotarget. 2016 Jan 19;7(3):3403-15
pubmed: 26655088
J Invest Dermatol. 2009 Jan;129(1):246-8
pubmed: 18650846
J Invest Dermatol. 2013 Jul;133(7):1879-89
pubmed: 23419694
J Am Acad Dermatol. 2018 May;78(5):973-982.e8
pubmed: 29273486
Ann Surg Oncol. 2016 Oct;23(11):3564-3571
pubmed: 27198511
Cancers (Basel). 2013 Feb 28;5(1):234-54
pubmed: 24216706
Arch Pathol Lab Med. 1985 Aug;109(8):716-21
pubmed: 3893381
J Clin Oncol. 2009 Aug 20;27(24):4021-6
pubmed: 19597021
Clin Cancer Res. 2013 Oct 1;19(19):5351-60
pubmed: 23922299
Cancer Immunol Res. 2013 Jul;1(1):54-63
pubmed: 24416729
Front Oncol. 2019 Jan 24;9:20
pubmed: 30733932
Hum Pathol. 2011 Oct;42(10):1385-90
pubmed: 21453956
JAMA Oncol. 2018 Sep 1;4(9):e180077
pubmed: 29566106
Cancer Res. 2015 Sep 15;75(18):3720-3727
pubmed: 26238782
Int J Clin Exp Pathol. 2014 Oct 15;7(11):7610-21
pubmed: 25550797
J Immunother Cancer. 2018 Jan 19;6(1):7
pubmed: 29347993
N Engl J Med. 2016 Jun 30;374(26):2542-52
pubmed: 27093365
J Am Acad Dermatol. 2014 Apr;70(4):637-643
pubmed: 24521828
Oncoimmunology. 2012 Nov 1;1(8):1420-1421
pubmed: 23243614
Clin Cancer Res. 2012 May 15;18(10):2872-81
pubmed: 22467679
J Am Acad Dermatol. 2010 Nov;63(5):751-61
pubmed: 20646783
J Invest Dermatol. 2017 Jan;137(1):197-206
pubmed: 27592799
J Natl Compr Canc Netw. 2018 Jun;16(6):742-774
pubmed: 29891526
J Am Acad Dermatol. 2018 Mar;78(3):433-442
pubmed: 29229574
Mod Pathol. 2011 Nov;24(11):1451-61
pubmed: 21765392
Cancer Immunol Res. 2017 Feb;5(2):137-147
pubmed: 28093446